The effect of rush immunotherapy with house dust mite in the production of IL-5 and IFN-γ from the peripheral blood T cells of asthmatic children

Journal of Korean Medical Science

Volumn 24, Issue 3, 2009, Pages 392-397

  Kim, Hyo Bin ^a   Jin, Hyun Seung ^b   Lee, So Yeon ^c   Kim, Ja Hyeong ^d   Kim, Bong Seong ^e   Park, Seong Jong ^b   Hong, Soo Jong ^b  

^a Inje University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Hallym University College of Medicine   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Gangneung Asan Hospital   (South Korea)

Author keywords

Asthma; House dust mite; Interferon ; Rush immunotherapy; T Cell

Indexed keywords

GAMMA INTERFERON; HOUSE DUST ALLERGEN; INTERLEUKIN 5;

ADOLESCENT; ANIMAL; ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESENSITIZATION; FEMALE; HOSPITALIZATION; HUMAN; IMMUNOLOGY; MALE; METABOLISM; PYROGLYPHIDAE; T LYMPHOCYTE;

ADOLESCENT; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; CHILD; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-5; MALE; PYROGLYPHIDAE; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES;

EID: 67649223947     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2009.24.3.392     Document Type: Article

References (33)

1. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341: 468-75.
2. Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002; 57: 306-12.
3. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2000; 2: CD001186.
4. Lack G, Nelson HS, Amran D, Oshiba A, Jung T, Bradlev KL, Giclas PC, Gelfand EW. Rush immunotherapy results in allergen-specific alterations in lymphocyte function and interferon-γproduction in CD4+ T cells. J Allergy Clin Immunol 1997; 99: 530-8.
5. Majori M, Caminati A, Corradi M, Brianti E, Scarpa S, Pesci A. T-cell cytokine pattern at three time points during specific immunotherapy for mite-sensitive asthma. Clin Exp Allergy 2000; 30: 341-7.
6. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI: specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997; 99: 450-3.
7. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy: a six-year follow-up study. Clin Exp Allergy 2001; 31: 1392-7.
8. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, Koivikko A, Koller DY, Niggemann B, Norberg LA, Urbanek R, Valvirta E, Wahn U. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109: 251-6.
9. Aalbers R, Van der Gaag R, Van Leeuwen J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4 antibody response. J Immunol 1983; 130: 722-6.
10. Moss RB, Hsu YP, Kwasnicki JM, Sullivan MM, Reid MJ. Isotypic and antigenic restriction of the blocking antibody response to rye grass pollen: correlation of rye group I antigen-specific IgG1 with clinical response. J Allergy Clin Immunol 1987; 79: 387-98.
11. Kim BS, Lee SK, Park HS, Hong SJ. The early changes of humoral immune response after rush immunotherapy with Dermatophagoides farinae and Dermatophagoides pteronyssinus in house dust mite sensitive asthmatic children. J Asthma Allergy Clin Immunol 2001; 21: 543-51.
12. Creticos PS, Adkinson NF Jr, Kagery-Sobotak A, Proud D, Meier HL, Naclerio RM, Lichtenstein LM, Norman PS. Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy. J Clin Invest 1985; 76: 2247-53.
13. Rak S, Lowhagen O, Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol 1988; 82: 470-80.
14. Shim JY, Kim BS, Cho SH, Min KU, Hong SJ. Allergen-specific conventional immunotherapy decreases IgE-receptor-mediated basophil histamine release. Clin Exp Allergy 2003; 33: 52-7.
15. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γsecretion in specific allergen-stimulated T cell cultures. J Immunol 1995; 154: 4187-94.
16. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993; 178: 2123-30.
17. Van Bever HP, Vereecke IF, Bridts CH, De Clerck LS, Stevens WJ. Comparison between the in vitro cytokine production of mononuclear cells of young asthmatics with and without immunotherapy (IT). Clin Exp Allergy 1998; 28: 943-9.
18. Pène J, Desroches A, Paradis L, Lebel B, Farce M, Nicodemus CF, Yssel H, Bousquet J. Immunotherapy with Feld 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J Allergy Clin Immunol 1998; 102: 571-8.
19. Mamessier E, Birnbaum J, Dupuy P, Vervloet D, Magnan A. Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy. Clin Exp Allergy 2006; 36: 704-13.
20. Akdis CA, Akdis M, Blesken T, Wymann D, Alkan SS, Muller U, Blaser K. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996; 98: 1676-83.
21. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, Akdis CA. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33: 1205-14.
22. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of inter-leukin 10 in specific immunotherapy. J Clin Invest 1998; 102: 98-106.
23. + T cells during specific venom immunotherapy. Clin Exp Allergy 2007; 38: 291-7.
24. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225-44.
25. Wasserfallen JB, God K, Schulman KA, Baraniuk JN. Development and validation of rhinoconjunctivitis and asthma symptom score for use as an outcome measure in clinical trials. J Allergy Clin Immunol 1997; 100: 16-22.
26. Jung T, Schauer U, HeusSeries C, Neumann C, Rieger C. Detection of intracellular cytokines by flow cytometry. J Immunol Methods 1993; 159: 197-207.
27. O'Brien RM, Byron KA, Varigos GA, Thomas WR. House dust mite immunotherapy results in a decrease in Der p 2-specific IFN-γand IL-4 expression by circulating T lymphocytes. Clin Exp Allergy 1997; 27: 46-51.
28. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997; 159: 4772-80.
29. Kim JH, Kim BS, Lee SY, Seo JH, Shim JY, Hong TJ, Hong SJ. Different IL-5 and IFN-γproduction from peripheral blood T cell subsets in atopic and nonatopic asthmatic children. J Asthma 2004; 41: 869-71.
30. Tamir R, Castracane JM, Rocklin RE. Generation of suppressor cells in atopic patients during immunotherapy that modulate IgE synthesis. J Allergy Clin Immunol 1987; 79: 591-8.
31. Lamb JR, Skidmore BJ, Green N, Chiller JM, Feldmann M. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med 1983; 157: 1434-47.
32. Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-γin immune regulation. I. IFN-γinhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol 1988; 140: 4245-52.
33. DeKruff RH, Fan Y, Umetsu DT. IL-4 synthesis by in vivo primed keyhole limpet hemocyanin-specific CD4+ T cells. J Immunol 1992; 149: 3468-76.